Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22984
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLa Joie, Renaud-
dc.contributor.authorAyakta, Nagehan-
dc.contributor.authorSeeley, William W-
dc.contributor.authorBorys, Ewa-
dc.contributor.authorBoxer, Adam L-
dc.contributor.authorDeCarli, Charles-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorGrinberg, Lea T-
dc.contributor.authorHuang, Eric-
dc.contributor.authorHwang, Ji-Hye-
dc.contributor.authorIkonomovic, Milos D-
dc.contributor.authorJack, Clifford-
dc.contributor.authorJagust, William J-
dc.contributor.authorJin, Lee-Way-
dc.contributor.authorKlunk, William E-
dc.contributor.authorKofler, Julia-
dc.contributor.authorLesman-Segev, Orit H-
dc.contributor.authorLockhart, Samuel N-
dc.contributor.authorLowe, Val J-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorMathis, Chester A-
dc.contributor.authorMcLean, Catriona L-
dc.contributor.authorMiller, Bruce L-
dc.contributor.authorMungas, Daniel-
dc.contributor.authorO'Neil, James P-
dc.contributor.authorOlichney, John M-
dc.contributor.authorParisi, Joseph E-
dc.contributor.authorPetersen, Ronald C-
dc.contributor.authorRosen, Howard J-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorSpina, Salvatore-
dc.contributor.authorVemuri, Prashanthi-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorMurray, Melissa E-
dc.contributor.authorRabinovici, Gil D-
dc.date2018-10-19-
dc.date.accessioned2020-04-14T04:01:27Z-
dc.date.available2020-04-14T04:01:27Z-
dc.date.issued2019-02-15-
dc.identifier.citationAlzheimer's & dementia : the journal of the Alzheimer's Association 2019; 15(2): 205-216en
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/22984-
dc.description.abstractWe sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [11C]PIB-positron emission tomography ([11C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. CL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Our study demonstrated the robustness of a multisite Centiloid [11C]PIB-PET study and established a range of pathology-based CL thresholds.en
dc.language.isoeng-
dc.subjectAlzheimer's disease neuropathologic changesen
dc.subjectCERADen
dc.subjectCentiloiden
dc.subjectHarmonizationen
dc.subjectNeuropathologyen
dc.subjectPittsburgh compound-Ben
dc.subjectPositron emission tomographyen
dc.subjectThalen
dc.subjectThresholden
dc.subjectβ-amyloiden
dc.titleMultisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.en
dc.typeJournal Articleen
dc.identifier.journaltitleAlzheimer's & dementia : the journal of the Alzheimer's Associationen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.en
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Anatomical Pathology, Alfred Hospital, Melbourne, Australiaen
dc.identifier.affiliationThe Florey Institute, The University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationHelen Wills Neuroscience Institute, University of California Berkeley, CA, USAen
dc.identifier.affiliationDepartment of Neurology, University of Pittsburgh, PA, USAen
dc.identifier.affiliationDepartment of Psychiatry, University of Pittsburgh, PA, USAen
dc.identifier.affiliationAlzheimer's Disease Research Center, University of Pittsburgh, PA, USAen
dc.identifier.affiliationDepartment of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USAen
dc.identifier.affiliationBiomedical Isotope Facility, MBIB Division, Lawrence Berkeley National Laboratory, CA, USAen
dc.identifier.affiliationDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Pathology, Stritch School of Medicine, Loyola University, Maywood, IL, USAen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Neurology, University of California, Davis, CA, USAen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Radiology, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationHelen Wills Neuroscience Institute, University of California Berkeley, CA, USAen
dc.identifier.affiliationAlzheimer's Disease Center, Department of Pathology, University of California Davis, CA, USAen
dc.identifier.affiliationDepartment of Pathology, University of Pittsburgh, Pennsylvania, USAen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Nuclear Medicine, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationDepartment of Radiology, University of Pittsburgh, PA, USAen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Neurology, University of California, Davis, CA, USAen
dc.identifier.affiliationDepartment of Neurology, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationMemory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USAen
dc.identifier.affiliationDepartment of Radiology, Mayo Clinic, Rochester, MN, USAen
dc.identifier.affiliationDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USAen
dc.identifier.doi10.1016/j.jalz.2018.09.001en
dc.type.contentTexten
dc.identifier.orcid0000-0002-8051-0558en
dc.identifier.orcid0000-0002-5832-9875en
dc.identifier.pubmedid30347188-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinResearch Support, N.I.H., Extramural-
dc.type.austinResearch Support, Non-U.S. Gov't-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Jan 20, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.